Clinical trial • Phase I • Other
Izicopan (INF904) for Healthy volunteers
Phase I trial of Izicopan (INF904) for Healthy volunteers. open-label, none/not specified-controlled. 8 participants.
Overview
- Trial Therapeutic Area
- Other
- Trial Disease
- Healthy volunteers
- Trial Stage
- Phase I
- Drug Modality
- Small molecule
Key dates
- Initial CTIS Submission Date
- 06-03-2026
- First CTIS Authorization Date
- 01-05-2026
Trial design
open-label, none/not specified-controlled Phase I trial in Netherlands.
- Open Label
- Yes
- Comparator
- None/Not specified
- Target Sample Size
- 8
Eligibility
Recruits 8 No vulnerable populations selected; only male participants are eligible; consent/assent process not specified in the available record..
- Vulnerable Population
- No vulnerable populations selected; only male participants are eligible; consent/assent process not specified in the available record.
Recruitment
- Planned Sample Size
- 8
- Recruitment Window Months
- 1
- Consent Approach
- Not specified in the available record.
Geography
- Total Number Of Sites
- 1
- Total Number Of Participants
- 8
Netherlands
- Earliest CTIS Part Ii Submission Date
- 27-04-2026
- Latest Decision Or Authorization Date
- 01-05-2026
- Processing Time Days
- 4
- Number Of Sites
- 1
- Number Of Participants
- 8
Sites
- Site Name
- Pharmaceutical Research Associates Group B.V.
- Department Name
- Program Management
- Contact Person Name
- Salah Hadi
- Contact Person Email
- salah.hadi@iconplc.com
- Number Of Participants
- 8
Sponsor
Primary sponsor
- Full Name
- InflaRx GmbH
- Organisation Type
- Pharmaceutical company
- Country Of Registered Address
- Germany
Investigational products
- Investigational Product Name
- 14C-LABELED IZICOPAN (INF904)
- Active Substance
- Izicopan (INF904)
- Modality
- Small molecule
- Frequency
- Single-dose
Related trials
Other published trials that may interest you.